PT-141 10MG

PT-141 10MG

PT-141, also known as BIMSB24 or Alisertib, is a compound originally developed for the treatment of cancer and leukemia due to its ability to inhibit the Aurora A protein. This compound was later explored in various research contexts beyond oncology.

Research Context

PT-141 has been studied extensively for its potential as an investigational agent, particularly for its role in regulating cell division and survival mechanisms. Its unique mechanism of action makes it a valuable tool in cellular biology and molecular research environments focused on understanding the behavior of cells under various conditions.

Research Overview

This compound is primarily used in research settings to investigate the effects of Aurora A inhibition on cellular processes, including cell cycle regulation and signaling pathways. Researchers utilize PT-141 to study its impact on various biological systems at a molecular level.

Key Research Focus Areas

• Inhibiting cell proliferation and inducing apoptosis in cancer cells.
• Investigating the role of Aurora A in cellular signaling pathways.
• Evaluating PT-141’s effects on cell cycle arrest mechanisms.
• Studying the impact of Aurora A inhibition on gene expression and protein levels.

Final Compliance Disclaimer

This product is intended for research use only. Not for human or animal consumption.